Standard Biotools (LAB) Shares Outstanding (Weighted Average) (2010 - 2026)

Standard Biotools (LAB) has 17 years of Shares Outstanding (Weighted Average) data on file, last reported at $388.2 million in Q1 2026.

• Quarterly Shares Outstanding (Weighted Average) rose 2.64% year-over-year to $388.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $388.2 million (up 2.64% YoY) and the FY2025 annual result came in at $381.6 million, up 8.03% from the prior year.
• Shares Outstanding (Weighted Average) grew to $388.2 million in Q1 2026 per LAB's latest filing, from $381.6 million in the prior quarter.
• Across five years, Shares Outstanding (Weighted Average) topped out at $388.2 million in Q1 2026 and bottomed at $77.0 million in Q1 2022.
• The 5-year median for Shares Outstanding (Weighted Average) is $294.1 million (2024), against an average of $228.7 million.
• The widest annual swing landed in 2023, when Shares Outstanding (Weighted Average) gained 0.09%; it then surged 370.5% in 2024.
• Tracing LAB's Shares Outstanding (Weighted Average) over 5 years: stood at $78.3 million in 2022, then climbed by 1.09% to $79.2 million in 2023, then jumped by 346.24% to $353.2 million in 2024, then climbed by 8.03% to $381.6 million in 2025, then gained by 1.72% to $388.2 million in 2026.
• Per Business Quant, the three latest LAB Shares Outstanding (Weighted Average) figures stand at $388.2 million (Q1 2026), $381.6 million (Q4 2025), and $380.5 million (Q3 2025).

Peer Comparison